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Abstract
Introduction: The aim of this study was to investigate the diagnostic performance of measuring antibodies to the
glycopeptidolipid (GPL) core antigen specific to Mycobacterium avium complex (MAC) in patients with rheumatoid
arthritis (RA).
Methods: We cross-sectionally investigated anti-GPL antibodies and radiographs of 396 patients with RA. A diagnosis
of MAC pulmonary disease (MAC-PD) was made according to the criteria by the American Thoracic Society and the
Infectious Diseases Society of America. Serum immunoglobulin A antibodies to MAC-specific GPL core antigen were
measured by an enzyme immunoassay. All patients with RA with abnormal shadows on chest x-rays underwent chest
computed tomography (CT). Bronchoscopy was performed on patients with negative cultures for MAC by
expectorated sputum and positive CT findings compatible with MAC-PD.
Results: Ten patients were newly diagnosed with MAC-PD. Eight individuals who already had diagnoses of MAC-PD
at the time of enrollment and nineteen who had negative expectorated sputum cultures for MAC and positive CT
images compatible with MAC-PD and who refused bronchoscopy were excluded from the following analysis. Anti-GPL
antibodies were detected in 12 of 369 patients. Eight of the ten patients with MAC-PD and 4 of 359 patients without
MAC-PD tested positive for the anti-GPL antibodies. The specificity and sensitivity were 99 % and 80 %, respectively.
Positive and negative predictive values were 67 %, and 97 %, respectively. When we analyzed diagnostic performance
of the antibodies in 57 patients with RA who had abnormal shadows on chest x-rays, the positive and negative
predictive values were 100 %, and 96 %, respectively. Twelve patients underwent bronchoscopy. Bronchoalveolar
lavage fluid (BALF) samples from six patients were positive for MAC, and BALF samples from the remainder were
negative. Anti-GPL antibodies were detected in the sera of all six patients with positive results for MAC by BALF
sampling, whereas the antibodies were not detected in the sera from the remainder with negative results for MAC by
BALF sampling.
Conclusions: The measurement of anti-GPL antibodies is useful as a supplementary diagnostic tool for MAC-PD in
patients with RA and may provide a new strategy, in combination with chest x-ray and CT, for differentiating MAC-PD
from other pulmonary comorbidities in patients with RA.
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Introduction
Although the emergence of biologic disease-modifying
antirheumatic drugs (DMARDs) has markedly changed
the course of rheumatoid arthritis (RA) and outcomes
for patients, concerns have been raised regarding the
higher risk of infection. Researchers in recent studies
have reported an increase in the prevalence of diseases
caused by nontuberculous mycobacteria (NTM) [1–4].
Eighty percent of patients with NTM diseases in Japan
have been infected with Mycobacterium avium complex
(MAC) [5]. MAC is now widely recognized as an im-
portant pathogen that causes chronic and progressive
pulmonary diseases in both immunocompetent and im-
munosuppressed patients.
The diagnosis of MAC-PD is complicated because, in
contrast to Mycobacterium tuberculosis, the contamin-
ation of clinical specimens by MAC can come from en-
vironmental sources such as water, dust, and soil, and
this organism may colonize the respiratory tract without
any accompanying invasive disease [6]. A diagnosis of
MAC-PD requires clinical findings and its repeated iso-
lation from sputum. Difficulties have also been asso-
ciated with discriminating MAC-PD from rheumatoid
lung disease in a clinical setting, because RA could de-
velop pulmonary manifestations, including rheumatoid
nodules, cryptogenic organizing pneumonia, bronchio-
litis obliterans, and bronchiectasis [7, 8]. The most fre-
quent finding by computed tomography (CT) in patients
with RA in one study was bronchiectasis [8]. Although
only 1–3 % of patients with RA clinically exhibit bron-
chiectasis, as many as 30 % of patients with RA manifest
bronchiectasis on high-resolution computed tomography
(HRCT) [9]. Bronchiectasis is considered to be both a
risk factor for and a consequence of NTM infections [9].
Kitada et al. [6, 10] recently established an enzyme
immunoassay (EIA) for the serological diagnosis of
MAC-PD by examining serum immunoglobulin A (IgA)
antibody levels against the glycopeptidolipid (GPL) core
antigen, which is a MAC-specific antigen. Unlike bron-
choscopy and sputum culture examinations, this test is
less invasive and provides more rapid diagnostic infor-
mation on MAC-PD.
In the present study, we focused on MAC-PD in pa-
tients with RA and conducted a cross-sectional obser-
vational study to investigate the clinical usefulness of
measuring anti-GPL antibodies in this patient population.
Methods
Patients
A cross-sectional observational study was conducted.
The study sample consisted of 396 patients who were
treated for RA between May and October 2013 at the
Hirose Clinic of Rheumatology, which is an outpatient
clinic located in Saitama prefecture in Japan. The
inclusion criteria for patients were fulfillment of the
2010 American College of Rheumatology/European
League against Rheumatism classification criteria for RA
[11]. Patients younger than 20 years of age and those
who had already been enrolled in a clinical study with
the intervention of a study drug were excluded. A total
of 824 patients with RA visited our clinic during the
study period. We randomly screened a total of 443 of
824 patients with RA, and a total of 381 patients with
RA (46.2 %) were not screened.
Sera from all participants were screened for anti-GPL
IgA antibodies, and all the participants underwent chest
radiography. For statistical analyses, recorded data,
including demographics, disease activity, comorbidities,
treatments, and laboratory data, were obtained at the
time of consent. All participants provided written in-
formed consent before study enrollment according to the
Declaration of Helsinki (World Medical Association
General Assembly, October 2008). This study was con-
ducted with the approval of the Hattori Clinic Institutional
Review Board (Hachioji, Tokyo, Japan), which was respon-
sible for reviewing and approving the study.
Diagnosis of MAC-PD
We defined MAC-PD according to the 2007 diagnostic
criteria for NTM lung disease proposed by the American
Thoracic Society and Infectious Diseases Society of
America [1]. Both of the following criteria had to be met
clinically: (1) pulmonary symptoms, nodular or cavitary
opacities on chest radiographs, or HRCT scans mani-
festing multifocal bronchiectasis with multiple small
nodules; and (2) appropriate exclusion of other diag-
noses. Only one of the following criteria was required
microbiologically: (1) positive culture results for at least
two separate expectorated sputum samples, (2) positive
culture results for at least one bronchial wash or lavage,
or (3) transbronchial or other lung biopsy specimens
with mycobacterial histopathological features. A diagno-
sis of MAC-PD infection required the fulfillment of the
clinical and microbiological criteria described above.
Enzyme immunoassay for anti-GPL antibodies
All serum samples were sent to the Life Science Institute,
Inc. (Tokyo, Japan), where a commercially available EIA
kit used to detect serum IgA antibodies specific to the
MAC-GPL core antigen (Capilia MAC Antibody ELISA;
TAUNS Laboratories, Shizuoka, Japan) was employed
with a previously described method [6]. The GPL core
antigen is a major cell surface antigen in MAC that is
absent on the cell wall of either M. tuberculosis or
Mycobacterium kansasii [10]. At the Life Science Institute,
the cutoff value was defined as 0.7 U/ml according to pre-
vious findings [6].
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Radiological evaluation
Chest x-rays were assessed by consensus reading by four
rheumatologists and one respiratory physician (WH, KI,
MM, TN, TU). All patients with RA who had abnormal
shadows on their chest x-rays underwent chest CT.
Chest CT images from patients with RA were reviewed
with consensus reading by one rheumatologist and one re-
spiratory physician experienced in CT (WH, TU). To
localize the infection by MAC, the lungs of each patient
were divided into 10 fields (right lung: S1 + S2, S3, S4 + S5,
S6, and S7 + S8 + S9 + S10; left lung: S1 + S2, S3, S4 + S5,
S6, and S8 + S9 + S10) according to Moore’s definition [12].
Each field was scored with reference to the presence of
bronchiectasis, centrilobular nodules, air space disease, a
cavity, and nodules larger than 5 mm as described in a
previous study [13]. The severity of bronchiectasis was
categorized as grade 1 (diameter of the bronchus less than
twice as large as the accompanying vessel), grade 2
(diameter of the bronchus at least twice as large as the
accompanying vessel), or grade 3 (cystic bronchiec-
tasis). The distribution of centrilobular nodules (size
less than 5 mm) was categorized as grade 1 (0–50 % of
the segment), grade 2 (50–100 % of the segment), or
grade 3 (100 % of the segment). Air space disease was
defined as an area of patchy or dense consolidation.
Air space disease and cavity formation were catego-
rized as grade 3 on the basis of a previous study in
which these two findings were closely related to clin-
ical features [14]. Nodular sizes larger than 5 mm were
also scored as grade 1. Grades of the 10 fields were
summed to calculate scores for these radiological find-
ings. Thus, the maximum scores of bronchiectasis,
centrilobular nodules, air space disease, cavities, and
nodules larger than 5 mm in both lungs were 30, 30,
30, 30, and 10, respectively. Scores for the extent of
MAC-PD were added to give total CT scores [13].
Thus, the maximum possible total CT score in both
lungs was 130.
Sputum
All patients with RA with abnormal findings on chest
CT compatible with MAC-PD submitted expectorated
sputum for examination on three consecutive days. An
early-morning specimen was collected in a sterile cup,
and it was immediately transported to the microbiology
laboratory at the Life Science Institute. The sputum
was examined and cultured for mycobacteria. Identifi-
cation of MAC was confirmed by TaqMan polymerase
chain reaction (Applied Biosystems, Foster City, CA,
USA) at the same laboratory. The patients whose ex-
pectorated sputum was negative for MAC were recom-
mended to undergo bronchoscopy at the Fukujuji
Hospital, which was performed once the patient’s con-
sent was obtained.
Statistical analysis
All data were analyzed using SAS software version 9.3
(SAS Institute, Cary, NC, USA). Demographics and
clinical characteristics were expressed as means and
standard deviations for continuous variables or as fre-
quencies and percentages for categorical variables. Com-
parisons between patients with RA with and without
MAC-PD were made using Student’s t test for continu-
ous variables. Pearson’s χ2 test was used for categorized
variables. All P values were two-tailed, and P values less
than 0.05 were considered significant. The Mann–Whitney
U test was used to compare the differences in titers of
anti-GPL antibodies between patients with and those
without MAC organisms in bronchoalveolar lavage
fluid (BALF) samples. Correlation coefficients between
the extent of MAC-PD on chest CT images and titers
of anti-GPL IgA antibodies were analyzed using a
simple regression analysis.
Results
Diagnosis of MAC-PD in enrolled patients
Because the level of anti-GPL antibodies has been re-
ported to reflect disease activity of MAC infection and to
decrease after successful antimicrobial chemotherapy [10],
eight patients who already had diagnoses of MAC-PD
at the time of enrollment were excluded from the fol-
lowing analyses. A total of 388 patients were screened
using chest x-rays, and 76 of these patients were found
to have abnormal shadows. These patients underwent
chest CT. Thirty-five of the seventy-six patients had ab-
normal CT images compatible with MAC-PD, and the
remaining forty-one patients had abnormal CT images
incompatible with MAC-PD. The 35 patients with ab-
normal CT images compatible with MAC-PD submit-
ted expectorated sputum. Four of these patients had
positive cultures for MAC and were diagnosed as
having MAC-PD; the others’ cultures were negative.
Bronchoscopy could be performed in 12 of the 31 pa-
tients who had negative expectorated sputum cultures
for MAC and positive CT findings. The BALF of 6 of
these 12 patients were positive for MAC, and these 6
patients were diagnosed as having MAC-PD; the others’
BALF samples were negative for MAC. The remaining
19 of the 31 patients who had negative expectorated
sputum cultures for MAC and positive CT images com-
patible with MAC-PD refused bronchoscopy. Five of
these nineteen patients tested positive for anti-GPL anti-
bodies, and the remaining fourteen tested negative for
these antibodies. We could not determine the presence or
absence of MAC-PD in these patients and excluded them
from the following statistical analyses. Consequently, we
analyzed 369 patients, including 10 with and 359 without
MAC-PD. Figure 1 describes the patient disposition from
screening until diagnosis of MAC-PD.
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Diagnostic performance of anti-GPL antibodies
Of the 369 patients, 12 tested positive for the anti-GPL
antibodies. Of the 12 anti-GPL antibody–positive pa-
tients, 8 were diagnosed with MAC-PD. Of the 357 anti-
GPL antibody–negative patients, 2 were diagnosed with
MAC-PD. The sensitivity, specificity, and accuracy of
the assay were 80 %, 99 %, and 98 %, respectively
(Table 1). On the basis of these data, the positive and
negative likelihood ratios of the test were estimated as 80.0
and 0.20, respectively. A pretest probability of MAC-PD in
this sample was 2.7 %. Positive and negative posttest prob-
abilities were calculated at 69 % and 0.54 %, respectively.
Positive predictive value was 67 %, and negative predictive
value was 97 %. Receiver operating characteristic curves
constructed for patients with and without MAC-PD
revealed an area under the curve (AUC) of 0.962.
We also analyzed the diagnostic performance of anti-
GPL antibodies in patients with RA who had abnormal
chest x-rays. We excluded 19 patients who had positive
CT images compatible with MAC-PD and negative ex-
pectorated sputum cultures for MAC and who refused
bronchoscopy; thus, 57 of 76 patients with abnormal
chest x-ray findings were subjected to this analysis. The
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Anti-GPL positive, N=6 
Anti-GPL negative, N=0
Fig. 1 Patient disposition flow chart. *Patients in this study who were diagnosed with Mycobacterium avium complex pulmonary disease (MAC-PD)
(n = 10 in total). #Patients in this study who were not diagnosed as having MAC-PD (n = 359 in total). BAL bronchoalveolar lavage, BALF bronchoalveolar
lavage fluid, GPL glycopeptidolipid
Table 1 Results of screening of sera for anti-GPL antibodies
from 369 patients with rheumatoid arthritis
RA with MAC-PD RA without MAC-PD Total
Anti-GPL ab, positive 8 4 12
Anti-GPL ab, negative 2 355 357
Total 10 359 369
Abbreviations: ab antibodies, GPL glycopeptidolipid, MAC Mycobacterium avium
complex PD pulmonary disease, RA rheumatoid arthritis
Variables are the number of patients unless otherwise indicated
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patients were 80 %, 100 %, and 97 %, respectively
(Table 2). Positive and negative predictive values were
calculated at 100 % and 96 %, respectively.
Relationship between chest CT findings and titers of
anti-GPL antibodies in patients with RA and MAC-PD
Anti-GPL antibodies were detected in the sera of all
six of the patients with positive results for MAC-PD
by BALF sampling, whereas these antibodies were not
detected in the sera of the six patients with negative
results for MAC-PD by BALF sampling. Titers of
anti-GPL antibodies are shown in Fig. 2. Chest CT im-
ages detected bronchiectasis, centrilobular nodules, nod-
ules larger than 5 mm, air space disease, and cavities in
100 %, 70 %, 50 %, 90 %, and 20 % of 10 patients with
MAC-PD, respectively. Of the 10 patients with RA with
MAC-PD, a positive correlation was observed between the
total CT scores of the involved segments, which repre-
sented the extent of MAC-PD, and the titers of anti-GPL
antibodies (r = 0.67, P = 0.049) (Fig. 3).
Comparison of patients with RA with versus without
MAC-PD
Baseline data for patients with MAC-PD (n = 10) and
without MAC-PD (n = 359) are shown in Table 3. Patients
with RA with MAC-PD had a longer disease duration
(P = 0.028), a lower body mass index (BMI) (P = 0.020),
and a smaller number of peripheral blood lymphocytes
(P = 0.044) than patients with RA without MAC-PD.
The patients with MAC-PD tended to be older than
those without MAC-PD, but no significant difference
was noted. The average age of the 369 patients who
were measured for anti-GPL antibodies in this study
was found to be older than that of the 381 patients who
were not screened for this study (64.3 ± 13.0 years ver-
sus 61.5 ± 13.1 years).
Discussion
In the present study, we assessed, for the first time to
our knowledge, the clinical usefulness of an EIA kit as a
supplementary diagnostic aid for MAC-PD in a large
series of patients with RA. Our results revealed that a
positive likelihood ratio, pretest probability, and positive
and negative posttest probabilities were 80.0, 2.7 %,
69 %, and 0.54 %, respectively. The positive likelihood
ratio of 80.0 indicated that detection of serum anti-GPL
antibodies has a large effect on increasing the probability
of MAC-PD presence. Pre- and posttest probability
values showed that the probability of MAC-PD presence
increases from 2.7 % to 69 % after obtaining a positive
test of serum anti-GPL antibodies. In addition, measur-
ing anti-GPL antibodies showed excellent positive and
negative predictive values and AUC for MAC-PD in pa-
tients with RA.
Although the specificity of the EIA kit was high, false-
positive EIA determinations were obtained in four pa-
tients. In these four patients, titers of anti-GPL antibodies
were positive at low values (0.7, 0.9, 1.8, and 2.0 U/ml).
Several explanations have been proposed for these false-
positive results. First, they could have been due to extra-
pulmonary infections by MAC [15]; however, this was
unlikely in our patients because of the lack of clinical
symptoms, negative culture results, and negative positron
Table 2 Diagnostic performance of anti-GPL antibodies in 57
patients with rheumatoid arthritis with abnormal shadows on
chest x-rays
RA with MAC-PD RA without MAC-PD Total
Anti-GPL ab, positive 8 0 8
Anti-GPL ab, negative 2 47 49
Total 10 47 57
Abbreviations: ab antibodies, GPL glycopeptidolipid, MAC Mycobacterium avium
complex PD pulmonary disease, RA rheumatoid arthritis
Variables are the number of patients unless otherwise indicated
Fig. 2 Anti-GPL antibody titers of 12 patients who underwent
bronchoscopy. Twelve patients with negative expectorated sputum
cultures for MAC and positive CT findings compatible with MAC
underwent bronchoscopy. BALF samples from six patients were positive
for MAC, and the remainder were negative. Titers of anti-GPL antibodies
in BALF samples were compared between the MAC-negative and
MAC-positive groups. *P= 0.0039. BALF bronchoalveolar lavage fluid,
CT computed tomography, GPL glycopeptidolipid, MAC Mycobacterium
avium complex
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Fig. 3 Relationship between anti-GPL antibody titers and radiological severity by computed tomography (CT) in 10 patients with rheumatoid
arthritis with Mycobacterium avium complex pulmonary disease. A positive correlation was observed between the severity of the disease and titers
of the antibodies (r = 0.67, P = 0.049). GPL glycopeptidolipid
Table 3 Characteristics of patients with rheumatoid arthritis with and without Mycobacterium avium complex pulmonary disease
Variable Overall (n = 369) RA with MAC-PD (n = 10) RA without MAC-PD (n = 359) P valuea
Age (yr) 64.3 ± 13.0 72.2 ± 6.1 64.1 ± 13.1 0.065
Female sex (%) 80.8 80.0 81.2 0.95
BMI (kg/m2) 21.8 ± 1.9 19.2 ± 2.3 21.8 ± 3.5 0.020
RA disease duration (yr) 13.0 ± 3.4 21.0 ± 4.7 11.2 ± 3.4 0.028
Current smoking (%) 11.0 0 11.4 0.26
RF positivity (%) 83.8 90.0 83.5 0.60
Steinbrocker stage III or IV (%)b 63.6 80.0 61.2 0.24
Steinbrocker class 3 or 4 (%)b 12.5 0 13.1 0.22
DAS28-CRP 2.8 ± 1.3 3.0 ± 0.8 2.8 ± 1.7 0.48
Peripheral blood lymphocytes (count/μl) 1736 ± 26.1 1322 ± 23.6 1740 ± 25.5 0.044
Oral corticosteroid use (%) 30.0 30.0 29.0 0.95
Prednisolone dosage (mg/day) 3.2 ± 1.4 3.7 ± 1.2 3.1 ± 1.5 0.56
MTX use (%) 66.7 60.0 67.4 0.62
MTX dosage (mg/wk) 7.5 ± 1.6 5.7 ± 1.5 7.6 ± 2.6 0.075
Use of immunosuppressive drugs, except for MTX (%)c 8.2 10.0 7.2 0.74
Use of biologic DMARDs (%) 52.9 60.0 52.4 0.65
Duration of biologic DMARD use (yr) NA 4.2 ± 2.6 4.0 ± 2.8 0.87
Diabetes mellitus (%) 9.8 20.0 8.9 0.23
Abbreviations: BMI body mass index, DAS28-CRP Disease Activity Score in 28 joints using C-reactive protein level, DMARD disease-modifying antirheumatic drug,
MAC-PD Mycobacterium avium complex pulmonary disease, MTX methotrexate, NA not applicable, RA rheumatoid arthritis, RF rheumatoid factor
Values are the percentage or mean ± standard deviation unless otherwise indicated. Bold values indicate significant differences (P < 0.05)
aBetween patients with RA with and without MAC-PD
bSteinbrocker et al. classification system [20] was used to define RA disease stages and classes
cImmunosuppressive drugs included tacrolimus, leflunomide, and mizoribine
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emission tomography findings. Second, they could have
been due to asymptomatic colonization with MAC organ-
isms from the environment [8]. Third, they could have
been due to non-specific binding of IgA in serum to the
GPL core antigen.
The average titer of anti-GPL antibodies in the
antibody-positive individuals in a previous study con-
ducted with patients with non-rheumatic disease [6] was
10.7 ± 7.9 U/ml, whereas it was 2.53 ± 1.94 U/ml in our
study. The lower titer of anti-GPL antibodies and two
false-negative cases observed in patients with RA could
be explained by the following reasons: (1) impaired anti-
body responses against the MAC GPL antigen by im-
munosuppressive therapy, (2) altered immune responses
to GPL core potentially governed by human leukocyte
antigen genes [16], and/or (3) less severe MAC-PD in
the two false-negative cases. Concomitant use of metho-
trexate (MTX) may affect the positivity and titers of
anti-GPL antibodies. In the present study, the average
dosage of MTX used for the enrolled patients was lower
than that commonly used in Western countries. Further
studies are needed to investigate anti-GPL antibody gen-
eration in patients with RA receiving higher dosages of
MTX.
The incidence of NTM in the Japanese general popula-
tion is estimated at 5.7/100,000/yr [17], but no data are
available for age-matched prevalence of MAC-PD. Con-
sidering the incidence of MAC-PD in Japanese general
population, the prevalence of MAC-PD in our study ap-
pears to be very high. We speculated that both intensive
examinations for MAC-PD among the enrolled patients,
comprising CT, sputum culture, and bronchoscopy, and
the older age of the patients in the present study might
be responsible for this high prevalence.
Differentiating MAC-PD from other pulmonary co-
morbidities, including RA-associated interstitial lung
disease, is challenging in clinical practice. The initial im-
aging study obtained for diagnosis of pulmonary comor-
bidity in patients with RA is almost always a chest x-ray.
When we analyzed the diagnostic performance of anti-
GPL antibodies in 57 patients with RA who had abnor-
mal shadows on their chest x-rays, the positive and
negative predictive values and accuracy of the assay were
estimated as 100 %, 96 %, and 97 %, respectively. Al-
though the number of the patients was small, these data
indicated promising diagnostic performance of anti-GPL
antibodies in this patient population. Furthermore, our
study demonstrates the usefulness of testing for this
antibody in patients with chest CT findings compatible
with MAC-PD. MAC organisms were detected in the
BALF of all six patients who had positive CT findings
compatible with MAC-PD and anti-GPL antibodies,
whereas the organisms were not detected in the BALF of
the other six patients who had negative anti-GPL
antibodies in spite of characteristic CT findings. These
results support the possibility that combining positive anti-
GPL antibodies and positive CT findings for MAC-PD
could yield an alternative diagnostic procedure for
MAC-PD, even in patients with negative expectorated
sputum culture results for MAC. Further investigations
based on a prospective cohort study recruiting patients
with RA with abnormal x-ray and CT findings are re-
quired to fully establish the usefulness of this antibody
detection in differentiating MAC-PD from other pul-
monary comorbidities. A cost-effectiveness analysis for
measuring anti-GPL antibodies in patients with RA is
also needed.
Measuring anti-GPL antibodies could be a useful tool
for evaluating disease severity and monitoring disease
activity of MAC-PD in addition to its diagnostic ability,
based on the following findings. First, the titers of the
antibodies showed significant correlation with the extent
of MAC-PD in patients with RA, as shown in Fig. 3.
Second, we found one patient whose serum level of anti-
GPL antibodies gradually declined after successful anti-
microbial chemotherapy (Additional file 1), suggesting
that the level of the antibodies reflected disease activity
of MAC infection. Further investigation is required to
establish this relationship in patients with RA.
The results of univariate analysis revealed that patients
with RA with MAC-PD had a longer disease duration, a
lower BMI, and a smaller number of peripheral lympho-
cytes (Table 3) than other subjects. However, cross-
sectional studies cannot establish causality; they can only
determine associations. Therefore, a longitudinal study is
required to identify risk factors for development of
MAC-PD in patients with RA.
Before initiating immunosuppressive treatment of RA,
screening for latent or chronic infectious diseases is
mandatory to ensure patient safety and continuation of
treatment without infectious events. Current guidelines
recommend screening tests for tuberculosis and hepatitis
virus in particular [18, 19]. Given the high diagnostic
performance of anti-GPL antibodies for diagnosing
MAC-PD in patients with RA and the clinical conse-
quences of this pulmonary disease, we recommend
measuring anti-GPL antibodies before starting treatment
of RA, especially in patients with abnormal chest x-rays
in regions or countries with moderate to high prevalence
of MAC-PD. Those patients who have positive tests for
anti-GPL antibodies should be examined with additional
pulmonary imaging and microbiological studies to diag-
nose MAC-PD in consultation with a pulmonologist.
Conclusions
Measuring anti-GPL antibodies showed high specificity
with preserved sensitivity and excellent positive likeli-
hood ratio, positive and negative predictive values, and
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AUC for MAC-PD in patients with RA. Screening for
MAC-PD using anti-GPL antibodies helps to identify pa-
tients who should undergo further examination for diag-
nosis of MAC-PD. The present study also demonstrates
that the titers of anti-GPL antibodies correlated with the
extent of MAC-PD in patients with RA. Anti-GPL anti-
bodies in combination with chest radiography and CT
may provide a new strategy for diagnosis and evaluation
of MAC-PD in patients with RA.
Additional file
Additional file 1: Changes of serum level of anti-GPL antibodies in
a MAC-PD patient with RA. The levels of the antibodies gradually
declined after successful antimicrobial chemotherapy with rifampicin,
ethambutol (EB), clarithromycin (CAM), and streptomycin (SM). Because of
skin rash, the therapeutic regimen was changed to erythromycin (EM).
Sputum specimens were successfully converted to negative. (TIFF 30 kb)
Abbreviations
ab: antibodies; AUC: area under the curve; BAL: bronchoalveolar lavage;
BALF: bronchoalveolar lavage fluid; BMI: body mass index; CAM: clarithromycin;
DAS28-CRP: Disease Activity Score in 28 joints using C-reactive protein level;
DMARD: disease-modifying antirheumatic drug; EB: ethambutol; EIA: enzyme
immunoassay; EM: erythromycin; GPL: glycopeptidolipid; HRCT: high-resolution
computed tomography; IgA: immunoglobulin A; MAC: Mycobacterium avium
complex; MTX: methotrexate; NA: not applicable; NTM: nontuberculous
mycobacteria; PD: pulmonary disease; RA: rheumatoid arthritis; RF: rheumatoid
factor; SM: streptomycin.
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